Rapamycin
mTOR inhibitor
- Datasheet: view or download
- Applications:mTOR inhibitor
Biochemicals & reagents
53123-88-9
Sirolimus
1) Kay, et al. (1991) Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 72 544 / 2) Mita, et al., (2003) The molecular target of rapamycin (mTOR) as a therapeutic target against cancer Cancer Biol. Ther. 2(4 Suppl 1), S169 / 3) Lamming, et al. ( 2012). Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335 1638 / 4) Sarkar et.al. (2009), Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies Cell Death and Differentiation 16, 46
914.17
-20°C
Rapamycin (53123-88-9) is a clinically useful immunosuppressant. Inhibits the response to interleukin-2 blocking activation of T- and B-cells.1 Rapamycin forms a complex with cytosolic FK-binding protein 12 (FKB12) that binds to mTOR Complex1(mTORC1) inhibiting the mammalian target of rapamycin (mTOR).2 Rapamycin also binds to mTORC2 leading to decreased glucose tolerance and insensitivity to insulin.3 Induces autophagy.4